Want to join the conversation?
$REGN will be starting a 10,000 patient long-term treatment phase 3 clinical study of Fasinumab in 1H16. The company anticipates reporting data from a 16-week study in osteoarthritis pain in 1H16. In the early-stage pipeline, $REGN will share data from phase 1 and 2 studies of Evinacumab, antibody ANGPTL3 for dyslipidemia in 1H16.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.